News & Media

Mydecine shareholders voted 99.939% in favour of approving the Arrangement and received final approval of the Supreme Court of British Columbia.

Patent pending formulation has the potential to further reduce patient anxiety as compared to pure psilocybin, when used in therapy or medical practice.

Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence.

Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence.

CEO Josh Bartch will participate in three upcoming conferences in September: H.C. Wainwright, Oppenheimer and Maxim

Partnering with such a revered institution is a significant reputational win for Mydecine Innovations.

Psychedelics could provide just the right push to overcome nicotine addiction patterns like smoking.

Chief Scientific Officer Rob Roscow said the research agreement demonstrates Mydecine's commitment to advancing psychedelic medicine.

CEO Joshua Bartach told investors the company made “groundbreaking progress” and discoveries in its psilocybin compound research and drug development program.

CEO Josh Bartch to participate in BTIG Biotechnology Conference (Aug.9-10) and Canaccord Genuity’s 41st Annual Growth Conference (Aug. 10-12).

BTV takes an inside look at how Mydecine and Mindleap Health are developing and commercializing innovative solutions for treating mental health problems.

Filing is part of continued efforts to grow Mydecine's robust IP portfolio as the company consistently files for new patents that offer high potential to expand psychedelics for medical use.

DRP Gazette, which reports on news from the Wall Street Grapevine, says Mydecine is a stock that investors could do well to keep in their watch lists.

Mydecine CEO Josh Bartch gives an in-depth presentation and answers questions on Mydecine and the market opportunity.

The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics.

Seeking Alpha takes a deep dive look into Mydecine from an investment perspective and the market opportunity with psychedelic-assisted therapeutic solutions.

Michaels talks in-depth about his background, role at Mydecine and what the market opportunities the company is focused on.

Josh Bartch, co-founder and CEO, discusses the possibility of Mydecine using the compounds MYCO-001 and 004 to enable smoking cessation.

Bob Marley’s family and others are getting in on the non-psychedelic, CBD version of magic mushrooms.

It‘s definitely an exciting time for Mydecine, with more positive coverage expected in the weeks and months ahead.

CEO Joshua Bartch said the upcoming trial is aimed at achieving safer and more accurate psychedelic-led psychotherapy results in a supervised setting

MYCO-004 is a patch-delivered tryptamine compound and its properties include short duration, transdermal, precision dosing, and long-term compound stability.

The Mydecine stock was in the news after Roth Capital Partners started covering the stock and gave it a buy rating.

Mydecine CEO Josh Bartch will participate in the ROTH Healthcare Private Company Forum and speak on the panel titled Next Wave of Psychedelic Drug Developers.

Meet Delic LIVE virtual events provide free pyschedelic education to all as psychedelic wellness is for everyone.

Roth Capital Partners (RCP) bestowed an eye-opening price target that instantly captured the market’s attention.

Josh Bartch, the CEO of Mydecine, discusses the origins of their work, their team, and current research and practices in the field.

Mydecine is the first to treat PTSD and smoking cessation with the natural form of psilocybin (MYCO – 001).

The four psychedelic drugs can eliminate cardiovascular risk issues and significantly reduce the half-life to less than two hours.

The program will enable the company to more rapidly screen hundreds of thousands of new molecules without the need to produce them.

The program will use artificial intelligence and machine learning to inform its drug discovery process.

William Cook, Interim CEO and Technical Director of the subsidiary company, MindLeap Health, talks about Version 2.0 of the MindLeap app launching soon.

A large majority appear to have never been reported before and could be vital to the critical effects of naturally-sourced mushrooms on human health and wellbeing.

Mr. Bartch’s corporate presentation will be available on-demand starting at 7:00 a.m. ET on June 17.

Part II: Michaels talks about the addressable market for PTSD, how quickly the industry for psychedelics is moving, and how big pharma may get involved.

COO discusses the expansion of its cultivation facilities in Canada, the possibility of genetically editing mushrooms, and the roadmap for next 12 months.

Chief Science Officer Rob Roscow said it will “enhance” the firm’s ability to “produce pharmaceutical-grade psilocybin at scale”

Mydecine Innovations Group is a key force driving this innovation and is bridging the gap between the two industries.

Company intends to spin off its U.S. cannabis assets and its interests in U.S. cannabis projects into a newly incorporated subsidiary (“SpinCo”).

Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics.

Mydecine CEO Josh Bartch will speak on the panel titled Investing in the Mental Health Crisis Through Psychedelics.

Roscow talks Mydecine’s upcoming phase 2a clinical trials on psylocibin-assisted PTSD treatments, barriers presented by COVID, and the new novel drug candidates.

LeadGen Labs partnership will considerably increase Mydecine’s synthesis capabilities of novel molecules.

Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End.

Participants include Josh Bartch - Co-founder, Chairman and CEO; Dean Ditto - Chief Financial Officer; and Allison Soss - Investor Relations.

Podcast discusses the company's novel research protocols, its relationship with legal psilocybin growers in Jamaica, and the future for psychedelic therapy.‍

Company will host a conference call and audio webcast that morning at 10:30 a.m. ET featuring remarks by Josh Bartch, CEO and Dean Ditto, CFO.

Mydecine and other companies are looking into natural medicine initiatives to improve the quality of life of individuals struggling with mental health disorders.

Move represents next steps in company's research and development process as it investigates the chemical compounds and potential therapeutic effects of natural psilocybin.

Mydecine believes that these drug candidates are unique and patentable in the United States and Canada.

Podcast discusses how the psychedelic experience is key to treating PTSD and how it may teach us about how psychedelics make the brain open to new ideas.

Fast growing biotech company becomes latest in a wave of migrations and graduations to the NEO Exchange.

Shadd Dales talks with Mydecine Innovations Chief Science Officer Rob Roscow about Mydecine’s three main operational pillars: IP/R&D, Clinical Trials and Technology.

Vote for the public companies that are leading the emergence of psychedelics as a form of mental health treatment.

With recent landmark progress in legalization efforts around the world, it’s clear we are in a psychedelic renaissance.

­In depth look at how psychedelic mental health solutions are gaining steam with elite athletes and researchers.

Mydecine appoints former Novartis Norway CEO Michel Rudolphie as President of European Operations and partners with Dr. David Erritzoe for research.

Mydecine’s principal business will focus on the development and commercialization of solutions for treating mental health problems through its psilocybin research and development.

The chief operating officer sat down with The Dales Report last week to discuss the company’s latest activity.

Josh Bartch, Co-Founder & CEO of Mydecine, talks to Shadd Dales of The Dales Report to put recent company events in context.

CEO Joshua Bartch tells Proactive the Colorado-based emerging biotech and life sciences company is making tremendous advancements.

Milestone means Mydecine is now able to access a quality source of product for research purposes and to sell and transfer to other licensed global research facilities.

The Dales Report takes a look at Mydecine Innovations Group and its position in the world of early-stage psychedelic investing.

Partnership Supports Mydecine’s Drug Development and Clinical Trials Pipeline; Provides Update on Debt Settlement.

Mydecine’s Chief Scientific Officer and Co-Founder Rob Roscow talks first harvest and commercial export of legal psychedelic psilocybin mushrooms.

Co-founder and CEO Joshua Bartch speaks to Truffle Report about the company’s psychedelics research program.

Digital health platform will combine telemedicine, on-demand mental health programs and advanced wellbeing analytics.

Mydecine panelists will discuss if Psychedelic Drug Design can Improve Safety and Efficacy for Medicine.

Mydecine's Chief Medical Officer offers a few hypotheses as to why PTSD in veterans can be difficult to treat.

Offering further strengthens Mydecine’s balance sheet and positions the Company for continued growth in 2021.

Mydecine Innovations Group Advisory Board Member Robin Carhart-Harris, PhD and David Nutt, MD, PhD provide viewpoint on industry progress.

Wu brings in an extensive network of experts in operation, clinical, market positioning and regulatory knowledge in the Pan Asia healthcare landscape.

With the move, the company is positioning its common shares to be traded on a senior exchange in Canada, providing exposure to more investors.

The research goal is to get a better understanding of when, where and how psilocybin is most appropriate for use in human therapeutics.

Mydecine submitted a formal application to list its common shares on the second largest exchange by market capitalization worldwide.

FN Media Group presents Microsmallcap.com market commentary on the companies that are commercializing psychedelic medicines.

New Atlas's Flipboard aggregates some of the top stories from around the world on the subject of psychedelics.

Mydecine is one of 17 companies to be included in the Horizons Psychedelic Stock Index Exchanged Traded Fund (ETF).

Prospectus filing is in connection with its bought deal offering previously announced on January 14, 2021.

Josh Bartch highlights how Mydecine Innovations Group is well positioned in the pharmaceuticals and consumer packaged goods industries.

Mydecine's Rakesh Jetly, MD joins HCPLive® to talk about how research is on the cutting edge of a breakthrough treating trauma.

The emerging biopharma and life sciences company announces that it has entered into an agreement with Canaccord Genuity Corp.

Mydecine announces that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp.

Microdose Psychedelic Insights, which provides Psychedelic industry insight and market intelligence, believes the future is bright for Mydecine.

MYCO Continues to Strengthen Board of Directors in Anticipation of Senior Exchange Listing Requirements.

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.

Investor Place reports that “The Times They Are A-Changin’” for psychedelic mental health treatments.

Mydecine Innovations Group files seven provisional patent applications with United States Patent and Trademark Office.

Financial Buzz highlights five companies, including Mydecine Innovations Group, that are leading research efforts into Psilocybin.

Microdose Psychedelic Insights breaks down all the psychedelic industry advancements made in the year 2020.

Study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.

Multi-bagger returns for several companies; Large and rising capital flows into the industry; Very favorable media coverage and public opinion.

Highlighting notable scientific achievements Harris has made towards advancing the psychedelic renaissance.

Mydecine Innovations Group is focused on developing and commercializing innovative solutions to treat mental health problems and enhance well being.

Mydecine has engaged ethica CRO, a full-service Contract Research Organization (“CRO”) that conducts and manages ethical clinical research.

Mydecine panellists discuss psychedelic solutions in speaker series moderated by Business Insider journalist Yeji Lee.

The year 2020 has been a really big year for magic mushrooms and the fast-paced growth of psychedelic medicine.

Leading FDA consultancy firm ProPharma Group to advise on drug development and clinical trial pipeline.

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends, provides update on Mydecine.

Canada continues to open the door for clinical research the effectiveness of psilocybin for mental health treatments.